What physicians can do to prevent suicide

David J. Muzina, MD
Director, Adult Inpatient Psychiatry; Director, Bipolar and Schizophrenia Clinics, Department of Psychiatry and Psychology, The Cleveland Clinic Foundation

Address: David J. Muzina, MD, Department of Psychiatry and Psychology, P57, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail muzinad@ccf.org

The author has indicated that he has received grant or research support from the AstraZenica and Eli Lilly corporations and is on the speaker's bureaus of the Pfizer, Eli Lilly, and Forest Pharmaceuticals corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

David J. Muzina, MD
Director, Adult Inpatient Psychiatry; Director, Bipolar and Schizophrenia Clinics, Department of Psychiatry and Psychology, The Cleveland Clinic Foundation

Address: David J. Muzina, MD, Department of Psychiatry and Psychology, P57, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail muzinad@ccf.org

The author has indicated that he has received grant or research support from the AstraZenica and Eli Lilly corporations and is on the speaker's bureaus of the Pfizer, Eli Lilly, and Forest Pharmaceuticals corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

David J. Muzina, MD
Director, Adult Inpatient Psychiatry; Director, Bipolar and Schizophrenia Clinics, Department of Psychiatry and Psychology, The Cleveland Clinic Foundation

Address: David J. Muzina, MD, Department of Psychiatry and Psychology, P57, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail muzinad@ccf.org

The author has indicated that he has received grant or research support from the AstraZenica and Eli Lilly corporations and is on the speaker's bureaus of the Pfizer, Eli Lilly, and Forest Pharmaceuticals corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.